Siemens to Offer Laboratory-Based SARS-CoV-2 Total Antibody Test with Time to First Result of 14 Minutes

The test, which detects both IgM and IgG, has demonstrated specificity and sensitivity of greater than 99%. The total antibody test will provide a clear view of a patient’s disease progression by identifying individuals infected with the virus who have developed an immune response to the virus, even if they were asymptomatic or never diagnosed with the disease. The test will add to Siemens’ robust diagnostics portfolio currently aiding in the prognosis, treatment and follow up of COVID-19 patients, such as its molecular Fast Track Diagnostics (FTD) SARS-CoV-2 test kit.

The test will be available on Siemens’ Atellica Solution immunoassay analyzer, which can run up to 440 tests per hour2 and will enable a result in just 14 minutes. In addition, the serology test also is expected to be available on the company’s expansive installed base of ADVIA Centaur XP and XPT analyzers, which deliver up to 240 tests per hour, with a result in 18 minutes. The availability of this test on these industry leading platforms will ensure more patients are tested in a shorter time.

Siemens anticipates availability of the total antibody test by late May 2020. The planned expanded production in the company’s manufacturing facility in Massachusetts, USA will accommodate more than 25 million tests per month in June and beyond. The company is pursuing Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) as well as the CE Mark. Comparable tests for Siemens Dimension Vista and Dimension EXL systems will also be pursued in the coming weeks to further expand clinical reach. In addition, the company intends to develop an IgG test to provide flexibility for testing needs as the pandemic evolves.

“Siemens Healthineers is working diligently to address the need for high-quality tests in the fight against COVID-19. This test is being designed with the precision and controls, sensitivity and specificity that laboratories have come to expect from our immunoassay tests,” said Deepak Nath, PhD, President, Laboratory Diagnostics, Siemens Healthineers. “I am especially proud of the dedication of our colleagues involved in development of this test—many of whom are based at the epicenter of the pandemic.”